2026 Global: Breast Cancer Screening Test Market-Competitive Review (2032) report
Description
The 2026 Global: Breast Cancer Screening Test Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for breast cancer screening test market by geography and historical trend. The scope of the report extends to sizing of the breast cancer screening test market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Hologic, Siemens Healthineers, GE Healthcare, Philips Healthcare, Fujifilm Holdings, Roche, Myriad Genetics, Exact Sciences, Natera, and Fujifilm (note: Fujifilm appears twice in some reports but is counted once here) are major companies shaping the global breast cancer screening test market through complementary strengths in imaging, molecular diagnostics, and AI-enabled tools. Hologic is recognized for its leadership in mammography and 3D breast tomosynthesis systems and widespread screening solutions that prioritize early detection and workflow efficiency. Siemens Healthineers and GE Healthcare provide advanced digital mammography, breast MRI, and ultrasound platforms with growing AI integration to improve sensitivity and diagnostic throughput across screening programs. Philips Healthcare and Fujifilm supply multimodal imaging systems and software for screening and diagnostic imaging, with product lines that span digital mammography to breast MRI and clinical informatics designed to support population screening initiatives.
Roche and Myriad Genetics bring molecular and genetic testing capabilities that complement imaging-based screening by assessing individual risk and guiding precision surveillance strategies; Roche’s diagnostics portfolio and Myriad’s hereditary risk panels expand options for risk stratification and personalized screening pathways. Exact Sciences and Natera extend the market into blood‑based and genomic assays—Exact Sciences with emerging biomarker and liquid‑biopsy approaches and Natera with circulating tumor DNA and hereditary cancer testing—enabling adjunctive screening, earlier detection in selected populations, and integration with imaging workflows. Independent specialized firms and newer entrants—such as DeepHealth/RadNet, Clairity, and AI vendors—are rapidly influencing the competitive landscape by delivering AI algorithms for detection, automated density assessment, and risk prediction that can be embedded into existing mammography pipelines to increase cancer detection rates and support risk‑based screening models.
Market dynamics among these ten companies are driven by technology convergence, regulatory milestones, and strategic partnerships that accelerate adoption of combined imaging–molecular screening approaches. Imaging incumbents (Hologic, Siemens Healthineers, GE, Philips, Fujifilm) focus on hardware upgrades, 3D imaging, automated breast ultrasound, and integrated AI to address sensitivity in dense breasts and workflow efficiency. Diagnostic and genomics players (Roche, Myriad, Exact Sciences, Natera) concentrate on risk assessment, liquid biopsy and genomic panels that identify individuals who may benefit from intensified imaging or tailored screening intervals. Cross‑sector collaborations, FDA authorizations for AI tools, and growing evidence from large real‑world and interventional studies are reshaping screening protocols toward personalized, multi‑modal strategies that combine imaging, molecular testing, and AI-driven risk stratification to improve early detection while managing false positives and resource utilization.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for breast cancer screening test market by geography and historical trend. The scope of the report extends to sizing of the breast cancer screening test market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Hologic, Siemens Healthineers, GE Healthcare, Philips Healthcare, Fujifilm Holdings, Roche, Myriad Genetics, Exact Sciences, Natera, and Fujifilm (note: Fujifilm appears twice in some reports but is counted once here) are major companies shaping the global breast cancer screening test market through complementary strengths in imaging, molecular diagnostics, and AI-enabled tools. Hologic is recognized for its leadership in mammography and 3D breast tomosynthesis systems and widespread screening solutions that prioritize early detection and workflow efficiency. Siemens Healthineers and GE Healthcare provide advanced digital mammography, breast MRI, and ultrasound platforms with growing AI integration to improve sensitivity and diagnostic throughput across screening programs. Philips Healthcare and Fujifilm supply multimodal imaging systems and software for screening and diagnostic imaging, with product lines that span digital mammography to breast MRI and clinical informatics designed to support population screening initiatives.
Roche and Myriad Genetics bring molecular and genetic testing capabilities that complement imaging-based screening by assessing individual risk and guiding precision surveillance strategies; Roche’s diagnostics portfolio and Myriad’s hereditary risk panels expand options for risk stratification and personalized screening pathways. Exact Sciences and Natera extend the market into blood‑based and genomic assays—Exact Sciences with emerging biomarker and liquid‑biopsy approaches and Natera with circulating tumor DNA and hereditary cancer testing—enabling adjunctive screening, earlier detection in selected populations, and integration with imaging workflows. Independent specialized firms and newer entrants—such as DeepHealth/RadNet, Clairity, and AI vendors—are rapidly influencing the competitive landscape by delivering AI algorithms for detection, automated density assessment, and risk prediction that can be embedded into existing mammography pipelines to increase cancer detection rates and support risk‑based screening models.
Market dynamics among these ten companies are driven by technology convergence, regulatory milestones, and strategic partnerships that accelerate adoption of combined imaging–molecular screening approaches. Imaging incumbents (Hologic, Siemens Healthineers, GE, Philips, Fujifilm) focus on hardware upgrades, 3D imaging, automated breast ultrasound, and integrated AI to address sensitivity in dense breasts and workflow efficiency. Diagnostic and genomics players (Roche, Myriad, Exact Sciences, Natera) concentrate on risk assessment, liquid biopsy and genomic panels that identify individuals who may benefit from intensified imaging or tailored screening intervals. Cross‑sector collaborations, FDA authorizations for AI tools, and growing evidence from large real‑world and interventional studies are reshaping screening protocols toward personalized, multi‑modal strategies that combine imaging, molecular testing, and AI-driven risk stratification to improve early detection while managing false positives and resource utilization.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
